Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Premier Biosoft Partner on Lipidomics Technologies

NEW YORK (GenomeWeb News) – Agilent Technologies and Premier Biosoft today said they will support the combination of each other's technologies to advance lipidomics research.

Agilent's time-of-flight and quadrupole time-of-flight mass spectrometers and Pathway Architect software used in conjunction with Premier's SimLipid 3.3 identification and quantification software will allow scientists to overcome obstacles that have stood in the way of lipid identification and analysis, the firms said.

"Just as challenging as mapping and sequencing the human genome is identifying and sequencing the thousands of lipid species involved in human metabolism," Daniel Kassel, Agilent’s senior director of LC/MS global marketing, said in a statement. "By utilizing this combined network of technologies, researchers can be confident in the analytical strength they have come to expect from Agilent and from the advanced lipid identification capabilities provided in Premier Biosoft’s SimLipid software."
 
Premier CEO Arun Apte added, "Our SimLipid software supports data from Agilent’s well-known MassHunter, Mass Profiler Professional and Pathway Architect software programs, creating an integrated workflow for the accurate and efficient identification and contextualization of lipids on metabolic pathways."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.